Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 205

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Peritoneal mesothelioma malignant+1

Not recruiting

Study on Talazoparib for Maintenance Treatment in Patients with Advanced Malignant Pleural or Peritoneal Mesothelioma After Initial Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Talazoparib
  • Sponsor:Hospices Civils De Lyon

Clear cell renal cell carcinoma

Not recruiting

Study on the Effectiveness of Relatlimab, Ipilimumab, and Nivolumab in Patients with High-Risk Clear Cell Renal Cell Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Non-small cell lung cancer+2

Not recruiting

Study of AMG 193 alone and combined with docetaxel for treatment of advanced MTAP-null solid tumors in adult patients

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AMG 193
  • Sponsor:Amgen Inc.

Endometrial cancer

Not recruiting

Study on Durvalumab, Paclitaxel, Carboplatin, and Olaparib for Patients with Advanced or Recurrent Endometrial Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Gastrointestinal stromal tumour

Not recruiting

Study on the Effectiveness of Lenvatinib for Patients with Advanced Gastrointestinal Stromal Tumors After Imatinib and Sunitinib Treatment Failure

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Centre Leon Berard

Cholangiocarcinoma

Not recruiting

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Incyte Corp.

B-cell lymphoma refractory

Not recruiting

Study on Tafasitamab with Gemcitabine, Oxaliplatin, and Rituximab for Patients with Aggressive B-cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Oxaliplatin
  • Sponsor:Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR

Anal squamous cell carcinoma

Not recruiting

Study of Spartalizumab and Drug Combination for Patients with Metastatic Anal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Centre Hospitalier Regional Universitaire

Glioblastoma

Not recruiting

Study on the Effectiveness and Safety of a Vaccine with Dendritic Cells for Patients with Newly Diagnosed Glioblastoma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Autologous Mature Dendritic Cells Loaded With Autologous Tumor Lysate
  • Sponsor:Heinrich-Heine-Universitaet Duesseldorf

Metastases to central nervous system+1

Not recruiting

Study on Nivolumab, Ipilimumab, and Bevacizumab for Patients with Non-Small Cell Lung Cancer Spread to the Brain

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Universitaetsklinikum Regensburg AöR

Non-small cell lung cancer+1

Not recruiting

Study on Durvalumab and Chemotherapy for Patients with Resectable Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Universitaetsklinikum Essen AöR

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing the Effects and Safety of FYB206 and Pembrolizumab with Chemotherapy in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Formycon AG

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.